-
![DYNAVAX_Superweek_001]( "Dynavax’s Evolving Business Model")
Dynavax’s Evolving Business Model2/9/2024Dynavax found a new revenue stream during COVID, and a way to grow market share in the absence of a market. Ryan Spencer describes the ups and downs, and his own journey to CEO role.
-
![Gyo Sagara LSL image]( "Where Are They Now? Ono Pharmaceuticals")
Where Are They Now? Ono Pharmaceuticals2/5/2024Ono Pharmaceuticals continues its quest to become a global biopharmaceutical company, after discovering and helping to launch one of the most successful cancer drugs, Opdivo, in the last decade.
-
![Ben Comer_450x300]( "Innovation From Animals And Evolution")
Innovation From Animals And Evolution2/1/2024Insights gleaned from a variety of animal species, and a deeper understanding of evolution aided by artificial intelligence, could help bring a new wave of therapies to market.
-
![Stephen Pagnotta Headshot_6.29.23]( "That Price Is WAC: Boehringer’s Push For Access To Humira Biosimilars")
That Price Is WAC: Boehringer’s Push For Access To Humira Biosimilars1/29/2024Boehringer Ingelheim's biosimilar commercial brand leader explains the company's two-tier pricing approach with Cyltezo, an interchangeable Humira biosimilar, and what new FDA guidance on interchangeability means for patients and physicians.
-
![Ben Comer_450x300]( "Pharmaceutical Scientists’ Salaries in 2023")
Pharmaceutical Scientists’ Salaries in 20231/15/2024The 2023 AAPS survey of pharmaceutical scientists' salaries showed a 6.7% jump over 2022, but the industry has work to do on closing the gender gap.
-
![Vivek Ramaswamy]( "Where Are They Now? Roivant")
Where Are They Now? Roivant1/15/2024"Where Are They Now?" looks back, and forward, at companies and executives previously covered in Life Science Leader magazine.
-
![David Younger_A-Alpha Bio]( "CEO Q&A: David Younger, Ph.D.")
CEO Q&A: David Younger, Ph.D.1/5/2024Life Science Leader catches up with David Younger, co-founder and CEO of A-Alpha Bio, about the promise of molecular glues, the challenges of starting up a new company, and collaborating with Big Pharma.
-
![Tiffany_Olson_Color_Print-2 (1)]( "Ahead Of The Curve On Radiopharmaceuticals")
Ahead Of The Curve On Radiopharmaceuticals1/1/2024Former president of Cardinal Health’s nuclear and precision health solutions group Tiffany Olson discusses her work on Bayer's Xofigo, and how she anticipated the rise of radiopharmaceuticals.
-
![Ben Comer_450x300]( "A New Year At Life Science Leader")
A New Year At Life Science Leader1/1/2024Life Science Leader wishes you a happy New Year and announces plans for 2024.
Ben Comer
Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.